<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title45.html">
                                    Title 45
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/45CFR156.html">Part 156
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 156.122  Prescription drug benefits.
                            </h3>
                            <p class="depth0"><em>(a)</em> A health plan does not provide essential health benefits unless  it:</p><p class="depth0"><em>(1)</em> Subject to the exception in paragraph (b) of this section,  covers at least the greater of:</p><p class="depth0"><em>(i)</em> One drug in every United States Pharmacopeia (USP) category and  class; or</p><p class="depth0"><em>(ii)</em> The same number of prescription drugs in each category and  class as the EHB-benchmark plan;</p><p class="depth0"><em>(2)</em> Submits its formulary drug list to the Exchange, the State or  OPM; and</p><p class="depth0"><em>(3)</em> For plans years beginning on or after January 1, 2017, uses a  pharmacy and therapeutics (P&T;) committee that meets the following  standards.</p><p class="depth0"><em>(i)</em> Membership standards. The P&T; committee must:</p><p class="depth0"><em>(A)</em> Have members that represent a sufficient number of clinical  specialties to adequately meet the needs of enrollees.</p><p class="depth0"><em>(B)</em> Consist of a majority of individuals who are practicing  physicians, practicing pharmacists and other practicing health care  professionals who are licensed to prescribe drugs.</p><p class="depth0"><em>(C)</em> Prohibit any member with a conflict of interest with respect to  the issuer or a pharmaceutical manufacturer from voting on any matters  for which the conflict exists.</p><p class="depth0"><em>(D)</em> Require at least 20 percent of its membership to have no  conflict of interest with respect to the issuer and any pharmaceutical  manufacturer.</p><p class="depth0"><em>(ii)</em> Meeting standards. The P&T; committee must:</p><p class="depth0"><em>(A)</em> Meet at least quarterly.</p><p class="depth0"><em>(B)</em> Maintain written documentation of the rationale for all  decisions regarding formulary drug list development or revision.</p><p class="depth0"><em>(iii)</em> Formulary drug list establishment and management. The P&T;  committee must:</p><p class="depth0"><em>(A)</em> Develop and document procedures to ensure appropriate drug  review and inclusion.</p><p class="depth0"><em>(B)</em> Base clinical decisions on the strength of scientific evidence  and standards of practice, including assessing peer-reviewed medical  literature, pharmacoeconomic studies, outcomes research data, and other  such information as it determines appropriate.</p><p class="depth0"><em>(C)</em> Consider the therapeutic advantages of drugs in terms of safety  and efficacy when selecting formulary drugs.</p><p class="depth0"><em>(D)</em> Review policies that guide exceptions and other utilization  management processes, including drug utilization review, quantity  limits, and therapeutic interchange.</p><p class="depth0"><em>(E)</em> Evaluate and analyze treatment protocols and procedures related  to the plan's formulary at least annually.</p><p class="depth0"><em>(F)</em> Review and approve all clinical prior authorization criteria,  step therapy protocols, and quantity limit restrictions applied to each  covered drug.</p><p class="depth0"><em>(G)</em> Review new FDA-approved drugs and new uses for existing drugs.</p><p class="depth0"><em>(H)</em> Ensure the issuer's formulary drug list:</p><p class="depth0"><em>(1)</em> Covers a range of drugs across a broad distribution of  therapeutic categories and classes and recommended drug treatment  regimens that treat all disease states, and does not discourage  enrollment by any group of enrollees; and</p><p class="depth0"><em>(2)</em> Provides appropriate access to drugs that are included in  broadly accepted treatment guidelines and that are indicative of general  best practices at the time.</p><p class="depth0"><em>(b)</em> A health plan does not fail to provide EHB prescription drug  benefits solely because it does not offer drugs approved by the Food and  Drug Administration as a service described in Sec. 156.280(d) of this  subchapter.</p><p class="depth0"><em>(c)</em> A health plan providing essential health benefits must have the  following processes in place that allow an enrollee, the enrollee's  designee, or the enrollee's prescribing physician (or other prescriber,  as appropriate) to request and gain access to clinically appropriate  drugs not otherwise covered by the health plan (a request for  exception). In the event that an exception request is granted, the plan  must treat the excepted drug(s) as an essential health benefit,  including by counting any cost-sharing towards the plan's annual  limitation on cost-sharing under Sec. 156.130 and when calculating the  plan's actuarial value under Sec. 156.135.</p><p class="depth0"><em>(1)</em> Standard exception request. For plans years beginning on or  after January 1, 2016:</p><p class="depth0"><em>(i)</em> A health plan must have a process for an enrollee, the  enrollee's designee,   or the enrollee's prescribing physician (or other prescriber) to request  a standard review of a decision that a drug is not covered by the plan.</p><p class="depth0"><em>(ii)</em> A health plan must make its determination on a standard  exception and notify the enrollee or the enrollee's designee and the  prescribing physician (or other prescriber, as appropriate) of its  coverage determination no later than 72 hours following receipt of the  request.</p><p class="depth0"><em>(iii)</em> A health plan that grants a standard exception request must  provide coverage of the non-formulary drug for the duration of the  prescription, including refills.</p><p class="depth0"><em>(2)</em> Expedited exception request. </p><p class="depth0"><em>(i)</em> A health plan must have a  process for an enrollee, the enrollee's designee, or the enrollee's  prescribing physician (or other prescriber) to request an expedited  review based on exigent circumstances.</p><p class="depth0"><em>(ii)</em> Exigent circumstances exist when an enrollee is suffering from  a health condition that may seriously jeopardize the enrollee's life,  health, or ability to regain maximum function or when an enrollee is  undergoing a current course of treatment using a non-formulary drug.</p><p class="depth0"><em>(iii)</em> A health plan must make its coverage determination on an  expedited review request based on exigent circumstances and notify the  enrollee or the enrollee's designee and the prescribing physician (or  other prescriber, as appropriate) of its coverage determination no later  than 24 hours following receipt of the request.</p><p class="depth0"><em>(iv)</em> A health plan that grants an exception based on exigent  circumstances must provide coverage of the non-formulary drug for the  duration of the exigency.</p><p class="depth0"><em>(3)</em> External exception request review. For plans years beginning on  or after January 1, 2016:</p><p class="depth0"><em>(i)</em> If the health plan denies a request for a standard exception  under paragraph (c)(1) of this section or for an expedited exception  under paragraph (c)(2) of this section, the health plan must have a  process for the enrollee, the enrollee's designee, or the enrollee's  prescribing physician (or other prescriber) to request that the original  exception request and subsequent denial of such request be reviewed by  an independent review organization.</p><p class="depth0"><em>(ii)</em> A health plan must make its determination on the external  exception request and notify the enrollee or the enrollee's designee and  the prescribing physician (or other prescriber, as appropriate) of its  coverage determination no later than 72 hours following its receipt of  the request, if the original request was a standard exception request  under paragraph (c)(1) of this section, and no later than 24 hours  following its receipt of the request, if the original request was an  expedited exception request under paragraph (c)(2) of this section.</p><p class="depth0"><em>(iii)</em> If a health plan grants an external exception review of a  standard exception request, the health plan must provide coverage of the  non-formulary drug for the duration of the prescription. If a health  plan grants an external exception review of an expedited exception  request, the health plan must provide coverage of the non-formulary drug  for the duration of the exigency.</p><p class="depth0"><em>(d)</em></p><p class="depth0"><em>(1)</em> For plan years beginning on or after January 1, 2016, a  health plan must publish an up-to-date, accurate, and complete list of  all covered drugs on its formulary drug list, including any tiering  structure that it has adopted and any restrictions on the manner in  which a drug can be obtained, in a manner that is easily accessible to  plan enrollees, prospective enrollees, the State, the Exchange, HHS, the  U.S. Office of Personnel Management, and the general public. A formulary  drug list is easily accessible when:</p><p class="depth0"><em>(i)</em> It can be viewed on the plan's public Web site through a clearly  identifiable link or tab without requiring an individual to create or  access an account or enter a policy number; and</p><p class="depth0"><em>(ii)</em> If an issuer offers more than one plan, when an individual can  easily discern which formulary drug list applies to which plan.</p><p class="depth0"><em>(2)</em> A QHP in the Federally-facilitated Exchange must make available  the information described in paragraph (d)(1) of this section on its Web  site in an HHS-specified format and also submit this information to HHS,  in a format and at times determined by HHS.</p><p class="depth0"><em>(e)</em> For plan years beginning on or after January 1, 2017, a health  plan providing essential health benefits must have the following access  procedures:</p><p class="depth0"><em>(1)</em> A health plan must allow enrollees to access prescription drug  benefits at in-network retail pharmacies, unless:</p><p class="depth0"><em>(i)</em> The drug is subject to restricted distribution by the U.S. Food  and Drug Administration; or</p><p class="depth0"><em>(ii)</em> The drug requires special handling, provider coordination, or  patient education that cannot be provided by a retail pharmacy.</p><p class="depth0"><em>(2)</em> A health plan may charge enrollees a different cost-sharing  amount for obtaining a covered drug at a retail pharmacy, but all cost  sharing will count towards the plan's annual limitation on cost sharing  under Sec. 156.130 and must be accounted for in the plan's actuarial  value calculated under Sec. 156.135.  [78 FR 12866, Feb. 25, 2013, as amended at 79 FR 30350, May 27, 2014; 80  FR 10871, Feb. 27, 2015]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ❤ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
